Actionable news
All posts from Actionable news
Actionable news in GNCA: GENOCEA BIOSCIENCES Inc,

Needham Reiterates Buy on Genocea Biosciences Inc Following Positive Interim Phase 2 Data in HSV-2

In a research report released Wednesday, Needham’s healthcare analyst Alan Carr reiterated a Buy rating on shares of Genocea Biosciences Inc (NASDAQ:GNCA), with a $22 price target, after the company announced six months interim results from the Phase 2 dose-optimization trial of GEN-003 in HSV-2 patients. Genocea shares reacted to the news, rising 8.31% to $6.39 on volume of 2,43 million shares.

Carr observed, “Overall, the GEN-003 program appears on track and we view...